Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06059586

Pre-Rehabilitation for Female Patients Undergoing Pelvic Radiotherapy

The purpose of this study is to examine the feasibility of adding pre-rehabilitation pelvic health physical therapy to standard of care radiation therapy treatment plan for female patients who have been diagnosed with cervical, vaginal, vulvar, uterine, or anal cancer and are a candidate for curative pelvic radiation with external beam. Participants will receive education on using a vaginal dilator for use during treatment and complete questionnaires looking at pain and sexual function.

Recruiting

Interested in participating?

Request Info

Key information

About this study

Because of the increasing survivorship rate, there is a need for research addressing the post-treatment side effects of pelvic pain and dyspareunia, due to the significant impact these side effects have on patients' quality of life. Current best practice from trained pelvic health physical therapists for addressing dyspareunia and pelvic pain due to vaginal stenosis after radiation therapy, is vaginal dilation. Vaginal dilators are cone shaped durable medical equipment that are inserted into the vagina with lubricant, to assist in patency of the vaginal canal and stretching of the pelvic floor muscles.

The primary objective of this pilot clinical trial is to assess the feasibility of implementing a collaborative, coordinated, and multidisciplinary initiative between radiation oncology and pelvic health physical therapy to answer the following questions: 1) What are the barriers and facilitators to the implementation of a pre-rehabilitation service for gynecological and female anal cancer patients undergoing pelvic radiation and 2) What is the potential clinical value of adding pre-rehabilitative pelvic health services, with an emphasis on vaginal dilator education and use, to the gynecological and female anal cancer radiation setting, in collaboration with radiation oncology staff, as a means of reducing pelvic pain and dyspareunia?

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Female
  • ≥ 18 years old at the time of informed consent
  • Ability to provide written informed consent and HIPAA authorization
  • Primary diagnosis of cervical, vaginal, vulvar, uterine, or anal cancer
  • Candidate for curative pelvic radiation with external beam, with or without brachytherapy, per radiation oncologist's discretion

Notes:

  • Can have prior and/or current modalities of treatment to address diagnosis including surgery and chemotherapy
  • Can receive radiation at any facility provided patient is able to perform Physical Therapy visits at IUH North/Schwarz Cancer Center

Exclusion criteria

  • Major medical illnesses or psychiatric impairments, which in the investigator's opinion will prevent administration or completion of the protocol therapy and/or interfere with follow-up.
  • Not a candidate for curative radiation therapy per radiation oncologist's discretion
  • Prior radiation therapy to the pelvis
  • Women who are pregnant or nursing

Treatment and study plan

Pelvic health therapy

Behavioral

Female Sexual Function Index (FSFI) and VAS Pain Scale Questionnaires, Physical Therapy Evaluation including Pelvic Floor Muscle Examination, Dilator Education

Dilator feasability

Device

Patient Adherence to Vaginal Dilation Questionnaire

Primary outcomes

  1. Feasability of implementation of pre-rehabilitation to radiotherapy

    Time frame: Baseline

    Recording the number of eligible patients for protocol that decline enrollment. The reason(s) for forgoing protocol intervention will be documented.

  2. Feasability of implementation of pre-rehabilitation to radiotherapy

    Time frame: Baseline

    The number of eligible patients that were not identified for protocol enrollment will be recorded and potential gaps in the screening process will be analyzed.

  3. Feasability of implementation of pre-rehabilitation to radiotherapy

    Time frame: Baseline

    The number of eligible patients identified, but not screened, for eligibility or not consented if eligible will be recorded.

  4. Feasability of implementation of pre-rehabilitation to radiotherapy

    Time frame: Baseline

    The duration of time from initial clinical presentation to being offered information of clinical study will be recorded.

  5. Feasability of implementation of pre-rehabilitation to radiotherapy

    Time frame: Baseline to 6 weeks

    The duration of time from enrollment on clinical study to being seen by physical therapy will be recorded.

  6. Feasability of implementation of pre-rehabilitation to radiotherapy

    Time frame: Baseline to 4 months

    The number of Female Sexual Function Index questionnaires will be recorded as completed, incomplete or not attempted. Reasons for submitting incomplete questionnaires or not submitting a questionnaire will be recorded.

Secondary outcomes

  1. Average score on the Visual Pain Rating Scale.

    Time frame: Immediately upon radiation completion, 4 weeks, 6 weeks, 8 weeks, 12 weeks, and 16 weeks post radiation

    Visual Analogue Pain Rating Scale 0-10

  2. Evaluate female sexual function based on questionnaire responses

    Time frame: Immediately upon radiation completion, 4 weeks, 6 weeks, 8 weeks, 12 weeks, and 16 weeks post radiation

    Female Sexual Function Index questionnaires (Likert scale)

  3. Percentage of adherence to dilator use

    Time frame: Immediately upon radiation completion, 4 weeks, 6 weeks, 8 weeks, 12 weeks, and 16 weeks post radiation

    Self-reported dilator adherence

Study contacts

Contact information is provided by the study sponsor or research team.

Namita Agrawal, MD

CONTACT

[email protected]

(317)944-2524

Sarah Dutkevich, RN

CONTACT

[email protected]

(317)278-5618

Sponsors and collaborators

Lead sponsor

Indiana University

Other

Registry information

Important dates

Study start
2024
Primary completion
2027
Study completion
2027
First posted
Sep 28, 2023
Registry last updated
Feb 27, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.